The Cure Sickle Cell Initiative: Catalyzing Progress via Innovative Interfaces Between NIH, Patients, Academics, ASH, and the Private Sector
Dr. Edward Benz provides some background on the discovery of sickle cell disease and development of the Cure Sickle Cell Initiative. Dr. Ify Osunkwo adds further perspectiv
A New Standard of Care for Children and Young Adults With T-cell Acute Lymphoblastic Leukemia
Dr. Teachey reviews a study that shows outstanding outcomes for children and young adults with T-cell acute lymphoblastic leukemia that have raised the bar and established
A concise review of a topic that illustrates the relationship of basic research to clinical hematology
Dr. David Sallman reviews studies that show the profound negative connotation of TP53 mutation in myelodysplastic syndromes and the immediate need for effective, biologically rational, targeted therapies.
Dr. Sheth discusses advances in therapies for β-thalassemia syndromes including optimization of gene therapy and the use of agents that leverage molecular targets.
Dr. Jenny Despotovic covers the expanded therapeutic repertoire currently emerging to treat immune thrombocytopenia (ITP) as understanding of ITP disease biology improves.
Dr. Jordan examines the emergence of targeted therapy for hemophagocytic lymphohistiocytosis, a striking inflammatory disorder familiar to hematologists.
Dr. Paneez Khoury provides an overview of the diagnosis and treatment of lymphocytic variant hypereosinophilic syndromes.
Dr. Schiffman and Dr. Maese discuss pediatric cancer susceptibility disorders and their relevance to hematology as highlighted in a 2016 American Association for Cancer Research workshop.
Dr. Abdel-Wahab provides an overview of histiocytoses or histiocytic neoplasms, some of the most challenging hematologic disorders to diagnose and categorize.
Drs. Sojitra, Arber, and George cover the 2017 joint guidelines from ASH and the College of American Pathologists on testing for the initial workup of acute leukemia.
Dr. Hoggatt discusses stem cell transplantation and looks at new, targeted conditioning approaches that have recently emerged, where the potential patient pool could be remarkably expanded with the advent of new gene therapy and editing strategies.
Dr. George and Dr. Czuchlewski cover the World Health Organization's 2016 updates to the classification of myeloid neoplasms.
November-December 2018Volume 15, Issue 6
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology